New combo therapy aims to boost immune attack on aggressive prostate cancer
Disease control
Recruiting now
This study tests whether adding immunotherapy (pembrolizumab) and a PARP inhibitor (olaparib) to standard radiation can better control high-risk prostate cancer. About 64 men with localized but aggressive prostate cancer will receive these treatments. The goal is to see if the co…
Phase: PHASE2 • Sponsor: Zin W Myint • Aim: Disease control
Last updated May 17, 2026 02:01 UTC